Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD20-CD19 cCAR in Relapsed/Refractory B Cell Malignancies
NCT04156178Phase 1Unknown
- Sponsor
- iCell Gene Therapeutics
- Start
- Aug 2018
- Primary completion
- Sep 2020
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CD20-CD19 cCAR T cells in B cell lymphoma and B-cell leukemia (BCL), sponsored by iCell Gene Therapeutics. Primary endpoints: Number of participants with dose limiting toxicity (DLT) at 28 days, Type of dose-limiting toxicity (DLT) at 28 days and 1 more. Status: unknown.
02
Drugs
CD20-CD19 cCAR T cells
03
Conditions
B cell lymphomaB-cell leukemia (BCL)
Beyond the preview
Go deeper on NCT04156178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04156178.